{"id":65964,"date":"2026-01-09T09:22:15","date_gmt":"2026-01-09T09:22:15","guid":{"rendered":"https:\/\/crowdfundjunction.com\/blog\/why-cormedix-stock-crashed-today-and-is-it-worth-buying-on-the-dip\/"},"modified":"2026-01-09T09:22:15","modified_gmt":"2026-01-09T09:22:15","slug":"why-cormedix-stock-crashed-today-and-is-it-worth-buying-on-the-dip","status":"publish","type":"post","link":"https:\/\/crowdfundjunction.com\/blog\/why-cormedix-stock-crashed-today-and-is-it-worth-buying-on-the-dip\/","title":{"rendered":"Why CorMedix stock crashed today and is it worth buying on the dip?"},"content":{"rendered":"

(Originally posted on : Invezz )<\/b>
\n<\/p>\n

\n

Investors are bailing on CorMedix (NASDAQ: CRMD) today after the biotech firm guided for up to $320 million in revenue for its fiscal 2026.<\/p>\n

The announcement<\/a> isn\u2019t sitting well with shareholders, primarily because CRMD\u2019s topline was roughly $400 million in the prior year, according to the preliminary full-year financials it posted on Thursday.<\/p>\n

Simply put, the NJ-headquartered firm expects its revenue to shrink this year, which seldom bodes well for investors. Following today\u2019s plunge, CorMedix stock is down over 50% from its 52-week high.<\/p>\n

CorMedix stock to remain subdued on DefenCath weakness<\/h2>\n


\n Copy link to section<\/span>
\n <\/a><\/p>\n

On July 1st, DefenCath will lose its temporary TDAPA reimbursement status and shift to a notably less favourable post-TDAPA add-on adjustment.<\/p>\n

What this means is that dialysis providers will receive lower institutional reimbursement, and CorMedix will face materially reduced net pricing.<\/p>\n

This will directly pressure its margins and undermine its near-term revenue visibility.<\/p>\n

Note that \u201cDefenCath\u201d was CorMedix\u2019s sole commercial product for a long time \u2013 and while the recent Melinta acquisition did expand its portfolio, those new revenue sources aren\u2019t yet material enough to offset the expected weakness in its antimicrobial catheter lock solution.<\/p>\n

This makes buying the dip in CRMD stock a rather risky proposition for serious investors.<\/p>\n

CRMD shares\u2019 technicals are just as concerning<\/h2>\n


\n Copy link to section<\/span>
\n <\/a><\/p>\n

CorMedix shares remain unattractive despite the sharp pullback, also because the management sees DefenCath sales sliding further to $140 million at the top end of its range in 2027.<\/p>\n

Moreover, it\u2019s not just fundamentals \u2013 the company\u2019s technicals are just as concerning. <\/p>\n

At the time of writing, CRMD is trading decisively below its major moving averages (MAs), indicating bears remain in control across multiple timeframes.<\/p>\n

Plus, the biotech stock\u2019s<\/a> long-term relative strength index (100-day) sits at about \u201c45\u201d currently \u2013 which means the broader downtrend isn\u2019t approaching exhaustion either.<\/p>\n

Note that insiders have predominantly unloaded CorMedix in the trailing 12 months, reinforcing that those closest to the company believe it was overvalued at north of $10.<\/p>\n

Taken together, these insights further strengthen the bear case for CRMD in 2026.<\/p>\n

Is it worth investing in CorMedix today?<\/h2>\n


\n Copy link to section<\/span>
\n <\/a><\/p>\n

On Thursday, CorMedix also said its chief executive, Joseph Todisco, is taking over as chairman of the board as well.<\/p>\n

This consolidation resides significant power in a single individual, reducing checks and balances that independent board oversight typically provides.<\/p>\n

For investors, this dual role can be unsettling \u2013 as it heightens governance risk and may complicate accountability.<\/p>\n

In the near term, this transition may mean uncertainty around strategic decision\u2011making, potentially undermining confidence in CRMD shares.<\/p>\n

What\u2019s also worth mentioning is that Wall Street had a consensus \u201cbuy\u201d rating and $19 price target on CorMedix heading into 2026.<\/p>\n

It\u2019s reasonable to assume, however, that following the DefenCath update today, at least some firms will choose to downwardly revise their estimates for CRMD. \u00a0<\/p>\n<\/p><\/div>\n

Source link <\/a>
\n
<\/p>\n","protected":false},"excerpt":{"rendered":"

(Originally posted on : Invezz ) Investors are bailing on CorMedix (NASDAQ: CRMD) today after the biotech firm guided for up to $320 million in revenue for its fiscal 2026. The announcement isn\u2019t sitting well with shareholders, primarily because CRMD\u2019s topline was roughly $400 million in the prior year, according to the preliminary full-year financials […]<\/p>\n","protected":false},"author":30,"featured_media":65965,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0},"categories":[39],"tags":[],"_links":{"self":[{"href":"https:\/\/crowdfundjunction.com\/blog\/wp-json\/wp\/v2\/posts\/65964"}],"collection":[{"href":"https:\/\/crowdfundjunction.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/crowdfundjunction.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/crowdfundjunction.com\/blog\/wp-json\/wp\/v2\/users\/30"}],"replies":[{"embeddable":true,"href":"https:\/\/crowdfundjunction.com\/blog\/wp-json\/wp\/v2\/comments?post=65964"}],"version-history":[{"count":0,"href":"https:\/\/crowdfundjunction.com\/blog\/wp-json\/wp\/v2\/posts\/65964\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/crowdfundjunction.com\/blog\/wp-json\/wp\/v2\/media\/65965"}],"wp:attachment":[{"href":"https:\/\/crowdfundjunction.com\/blog\/wp-json\/wp\/v2\/media?parent=65964"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/crowdfundjunction.com\/blog\/wp-json\/wp\/v2\/categories?post=65964"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/crowdfundjunction.com\/blog\/wp-json\/wp\/v2\/tags?post=65964"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}